Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc.
Arcus Biosciences Inc. (RCUS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Suvretta Capital Management Aaron Cowen | 4,776,423 | $147,257,121 | -6% | 2.69% |
| 2. | Citadel Investment Group Ken Griffin | 3,135,057 | $96,653,807 | +136% | 0.01% |
| 3. | Woodline Partners Michael Rockefeller And Karl Kroeker | 3,007,798 | $92,730,412 | -21% | 0.29% |
| 4. | Siren L.L.C. Raymond Debbane | 2,420,430 | $74,621,857 | -20% | 1.51% |
| 5. | Fisher Asset Management Ken Fisher | 2,139,396 | $65,957,578 | -3% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.06 | 20,000 | $201,200.00 | 28,400 | 2025-02-27 | Filing | |
| $10.18 | 19,800 | $201,465.00 | 2,554,160 | 2025-02-27 | Filing | |
| $11.00 | 1,363,636 | $14,999,996.00 | 31,424,760 | 2025-02-18 | Filing | |
| $21.00 | 15,238,095 | $319,999,995.00 | 30,061,124 | 2024-01-29 | Filing | |
| $19.26 | 1,010,000 | $19,452,600.00 | 14,823,029 | 2023-06-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.00 | 2,827 | $84,810.00 | 39,581 | 2026-08-21 | Filing | |
| $29.40 | 268 | $7,878.40 | 822,240 | 2026-07-10 | Filing | |
| $28.61 | 19,799 | $566,409.79 | 822,508 | 2026-07-10 | Filing | |
| $30.05 | 48,502 | $1,457,630.61 | 842,307 | 2026-07-09 | Filing | |
| $29.66 | 6,431 | $190,740.24 | 890,809 | 2026-06-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 31,424,760 | $968,825,351 | 58.76% | |
| 2. | 16,416,249 | $506,112,958 | 0.01% | |
| 3. | 6,029,484 | $185,888,992 | 0.01% | |
| 4. | 5,895,448 | $181,756,661 | 0.03% | |
| 5. | 4,475,528 | $137,980,528 | 0.01% |
News See All
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2026 Earnings Call Transcript
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2026 Earnings Call Transcript May 5, 2026Arcus Biosciences, Inc. misses on earnings expectations. Reported EPS is $-1.02 EPS, expectations were $-0.92.
Arcus Biosciences, Inc. (NYSE:RCUS) Q4 2025 Earnings Call Transcript
Arcus Biosciences, Inc. (NYSE:RCUS) Q4 2025 Earnings Call Transcript February 25, 2026Arcus Biosciences, Inc. beats earnings expectations. Reported EPS is $-0.89, expectations were $-1.11.
Here's What Analysts Think About Arcus Biosciences (RCUS)
Arcus Biosciences, Inc. (NYSE:RCUS) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Arcus Biosciences, Inc.
12 Best Immunotherapy Stocks to Buy According to Hedge Funds
In this article, we will look at the 12 Best Immunotherapy Stocks to Buy According to Hedge Funds.
Arcus Biosciences Inc. (RCUS) Posts Positive Results on Kidney Cancer Drug Trials
Arcus Biosciences Inc. (NYSE:RCUS) is one of billionaire Steve Cohen’s 10 small-cap stock picks with huge upside potential. On October 6, Arcus Biosciences Inc.
Billionaire Steve Cohen's 10 Small-Cap Stock Picks with Huge Upside Potential
In this article, we will examine Billionaire Steve Cohen's 10 Small-Cap Stock Picks with Huge Upside Potential.
Jim Cramer Shed Light on These 14 Stocks
On Wednesday’s episode of Mad Money, host Jim Cramer discussed why the market is highly favorable for active investors.
Arcus Biosciences' Pancreatic Cancer Drug Quemliclustat Receives Orphan Drug Designation from FDA
Arcus Biosciences Inc. (NYSE:RCUS) is one of the biotech stocks to buy according to Wall Street analysts.
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.
Hedge Fund Resource Center